Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balstilimab in HPV-positive Oropharyngeal Cancer With Persistent HPV Detection
NCT05363709Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label, single-arm trial of balstilimab in oropharyngeal cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 2 years and Clearance of virus in plasma cfDNA at 2 years. Planned start Oct 2023; status: withdrawn.
02
Drugs
balstilimab
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT05363709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363709.